Stories by Nature magazine

Amid a COVID surge in Africa, vaccine promises from richer nations are not enough to bring an early end to the pandemic, experts say

Complacency and a coronavirus variant help to explain why the country, once a pandemic success story, couldn’t withstand the surge now rocking South America

Partial SARS-CoV-2 sequences from early outbreaks in Wuhan were removed from a U.S. government database by the scientists who deposited them

Scientists are searching for explanations to disappointing final-stage trial results. These insights could help guide the future development of mRNA vaccines

High-resolution images suggest the star spewed out so much dust that its brightness dropped by two thirds in 2020

The pandemic is teaching us key lessons about how people respond to crisis and misinformation, and it is spurring changes in the way scientists study public health questions

A trove of new detections suggests that the bursts could be the result of at least two separate astrophysical phenomena

An examination of the arguments that SARS-CoV-2 escaped from a lab in China and the science behind them

Many scientists say there is not enough evidence that Biogen’s aducanumab is an effective therapy for the disease

A conversation with Eric Lander during his first day as the director of the White House Office of Science and Technology Policy

The International Society for Stem Cell Research relaxed the famous 14-day rule on culturing human embryos in its latest research guidelines

Allegations that COVID escaped from a Chinese lab make it harder for nations to collaborate on ending the pandemic—and fuel online bullying—some scientists say

Key questions remain about how quickly B.1.617 variants can spread, their potential to evade immunity and how they might affect the course of the pandemic

Preliminary results from a trial of more than 600 people are the first to show the benefits of combining different vaccines

Their structures were once controversial. Now researchers have discovered quasicrystals in the aftermath of a 1945 bomb test

People older than 80 who waited 11 to 12 weeks for their second jab had higher peak antibody levels than did those who waited only three weeks

In California’s San Joaquin Valley, some researchers are turning political to address the social determinants of health

Hopes are high for a class of drug that could treat neurodegenerative conditions—but a recent clinical trial has brought the field up short

Hopes were high for drugs designed to lower levels of a mutant protein, but development has stalled

The development from the Biden administration draws cheers from public health researchers and ire from drugmakers

It took just four months to reach this global milestone, and hitting the two-billion mark could happen even faster, say scientists

Experimental anomalies have sent researchers scrambling to concoct new explanations

Preliminary results suggest the vaccine is up to 77 percent effective in young children, but researchers await larger studies

The virus is spreading faster than ever before in the country despite previous high infection rates in megacities, which should have conferred some protection